

NZX Announcement

1 April 2020

Resignation of Director

Truscreen Limited (“the Company”) announces that prominent New Zealand gynaecologist, Dr. Ron Jones has retired from the board of the Company as at 31 March 2020. Dr. Jones has also stepped down from the Company’s Medical Advisory Board (“MAC”). The board of the Company will be reduced to four directors. The MAC will also be reduced to a committee of two members.

Dr. Jones joined the board as a non-executive director on 19 October 2017 and provided counsel to the Company on the development of and successful commercialisation of the Company’s Truscreen T2 cervical cancer screening device. He also provided an important link between the board and the MAC in relation to the MAC’s development of clinical trial protocols and analysis of clinical trial results.

Dr. Jones was an early key contributor of cervical cancer screening trial results from Auckland Hospital that significantly added to the benchmark datasets on which the Truscreen technology was developed.

On behalf of the board, the Truscreen team and fellow members of the MAC, we thank Dr. Jones for his contributions to Truscreen and extend our best wishes for all his future endeavours in his retirement.

Tony Ho
Chairman

- ENDS -

For more information, visit www.truscreen.com or contact:

TruScreen

Tony Ho
Chairman

tonyho@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>